Editas Medicine Strikes License Deal With Vertex Pharmaceuticals — Update
By Dean Seal
Editas Medicine has agreed to license Vertex Pharmaceuticals its Cas9 gene editing technology for ex vivo gene editing medicines targeted at sickle cell disease and beta thalassemia.
The clinical-stage genome editing company said Wednesday that under the terms of the agreement, Vertex will obtain a non-exclusive license for the technology in medicines targeting the BCL11A gene in the fields of sickle cell disease and beta thalassemia, which includes the cell-based gene therapy Casgevy.
The deal extends Editas' cash runway into 2026, the company said.
In a Securities and Exchange Commission filing, Editas said it would get an upfront cash payment of $50 million as part of the licensing deal. It is also eligible for an additional $50 million contingent upfront payment.
The company would also be entitled to license fees between $10 million and $40 million annually, including certain sales-based fee increases, through 2034, according to the filing.
Editas will have to pay a mid-double-digit percentage of amounts received from Vertex under the deal to The Broad Institute and the President and Fellows of Harvard College as it relates to Cas9 technology licensed from them.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 13, 2023 12:33 ET (17:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth